Dermatology and Therapy

Papers
(The H4-Index of Dermatology and Therapy is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis107
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials92
Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study85
Application of Comfort Therapy under eCASH Concept in Acute and Chronic Wound Treatment60
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry60
Hair Shaft Abnormalities as a Dermoscopic Feature of Mycosis Fungoides: Pilot Results52
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis 49
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study49
Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis45
Dermatologic Care of Hair in Transgender Patients: A Systematic Review of Literature44
Adverse-Event Reports in Over-the-Counter Topical Acne Drug Products Containing Benzoyl Peroxide from a Specific Pharmaceutical Company in the USA43
Sexual Dysfunction in Chronic Urticaria: A Systematic Review42
Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments41
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis39
Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review39
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials39
Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists36
Patients with Chronic Urticaria Remain Largely Undertreated: Results from the DERMLINE Online Survey36
Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence34
Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children33
Emerging Systemic Treatments for Atopic Dermatitis33
Postinflammatory Papule: A Tentative New Designation for Acne Vulgaris33
Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review32
Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?32
Development of a Predictive Model for Screening Patients with Psoriasis at Increased Risk of Psoriatic Arthritis31
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study30
Epidemiology and Burden of Pediatric Atopic Dermatitis in China29
Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada28
A Qualitative Analysis of Provider Notes of Atopic Dermatitis-Related Visits Using Natural Language Processing Methods28
0.096298217773438